BTK and graft versus host disease: The results of preclinical studies from autoimmune animal models are promising, and several phase 1 and phase 2 clinical trials with BTK inhibitors were initiated in patients with immune disorders, such as RA, SLE, SM, PV, AIHA, ITP, and GVHD.